About us
Advanced medical technology with a Swedish heritage
Neola Medical is on an exciting journey to bring innovation to patients worldwide. With a highly skilled and dedicated team, we are developing a medical device with the potential to save lives and improve quality of life for preterm born babies. Our work combines science, technology, and compassion, driven by the vision to upgrade the standard of neonatal intensive care and give every child the strongest possible start in life.
A word from our CEO Hanna Sjöström
“At Neola Medical, our mission is to provide preterm born babies with a stronger and safer start in life. By offering non-invasive, continuous, real-time lung monitoring with our innovative medical technology, Neola®, we aim to detect complications immediately, empowering healthcare professionals with the tools they need to make life-saving decisions. We are proud to be at the forefront of a new era in neonatal care, upgrading the care that these fragile patients currently receive and filling a unique market gap for pediatric medical devices, where every breath counts, and every life has the chance to thrive.”
Kind regards,
Hanna Sjöström
CEO, Neola Medical AB
Hanna Sjöström
CEO
Our vision: Advance neonatal intensive care worldwide
Several factors suggest that Neola® has the potential to evolve and upgrade the care of preterm born babies:
- Unmet Clinical Need – 15 million babies are born preterm each year, with lung complications as a leading cause of mortality and long-term disability.
- Innovative Technology – Patented GASMAS method developed at Lund University, adapted for safe, non-invasive lung monitoring.
- Strong Market Potential – Pediatric devices represent an underdeveloped and fast-growing MedTech segment with recurring revenue opportunities from disposable probe sets.
- Scalable Business Model – Combination of one-time device sales and recurring revenue from single-use disposables ensures strong scalability and predictable revenue streams.
- Proven Team & Network – Experienced leadership with expertise in MedTech commercialization, supported by collaborations with leading NICUs in Sweden and the U.S.
Building on a historic Swedish legacy of medical technology innovation
Sweden has made invaluable contributions to global healthcare, specifically in neonatal intensive care. As a result, the survival rate of preterm born babies has increased to almost 90 percent. Such was not the case in the 1970s, when modern neonatal care was first introduced. At that time, the mortality rate of children weighing under one kilo was over 90 percent. Since then, Sweden has helped develop world class neonatal intensive care, built on a foundation of the latest technology and nurturing methods that involve parents as well.
Following in the footsteps of diagnostic ultrasound, which was developed in the 1950’s in Lund, Sweden, Lund-based medical technology innovation once again has the potential to advance health care globally.
Company Milestones
2005
2016
Neola Medical AB is founded and headquartered in Lund, Sweden. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.
Addressing a critical medical need
Every year, around 15 million babies worldwide — about one in ten — are born preterm (before 37 weeks of pregnancy), many with underdeveloped lungs often unable to supply the body with oxygen. Preterm born babies often require neonatal intensive care, and approximately 1.1 million still die annually due to serious lung conditions. Preterm birth is one of the leading causes of death for babies under five. Even for those who survive, the risks of long-term complications remain high.
The goal with our innovative medical device, Neola®, is to enable earlier detection of complications, empower faster and more informed clinical decisions, and ultimately contribute to better care, fewer days in intensive care, and healthier lives for preterm born babies.
Addressing an urgent global need
The development of medical technology has focused almost entirely on devices for adults, leaving children, and especially newborns, with far fewer dedicated solutions. This gap has been recognized by the U.S. Food and Drug Administration (FDA), which has highlighted the urgent need for more pediatric medical devices. Stanford University launched the Stanford Impact1 program in 2023 with the vision of improving the health, safety and quality of life of pediatric and maternal patients globally. The same year, Neola Medical was selected as a Stanford Impact1 company, receiving support through the Stanford Impact1 program.
With increased regulatory focus on pediatric medical devices and the United Nations’ goal of reducing preventable neonatal mortality (SDG 3.2), Neola® is positioned to help advance neonatal care worldwide.
Neola Medical Headquarters
Neola Medical was founded in 2016 and is headquartered at Ideon Science Park in Lund, Sweden. At our offices in Lund, you will find all employees of Neola Medical.
Ideon Science Park is Sweden’s oldest and largest science park, and one of the country’s best-known innovation hubs. In 2019, it became the first science park in the world to be certified by the United Nations.
Neola Medical U.S. Office
In addition to Neola Medical’s headquarters in Lund, the company expanded its presence in the U.S. by opening an office at Nordic Innovation House in Palo Alto, Silicon Valley and establishing a subsidiary in the U.S. as part of the upcoming launch of Neola® in the American market.
Supporting proactive care
Neola® aim to allow healthcare teams to respond instantly to changes in lung function, helping prevent complications from escalating and reducing the need for invasive procedures.
Making care safer
Continuous monitoring with Neola® aim to reduce reliance on painful or risky procedures like repeated x-rays and blood tests, making care safer and more comfortable for the most vulnerable patients.
Upgrading neonatal care
Invest in Neola Medical
At Neola Medical, our mission is to provide preterm born babies with a stronger and safer start in life. Through our innovative medical device, Neola®, we aim to advance neonatal intensive care by offering non-invasive, continuous, real-time lung monitoring, with the potential to support proactive care, reduce morbidity and improve quality of life for these vulnerable patients.
"We aim to detect lung complications immediately, giving healthcare professionals the tools they need to make life-saving decisions."
– Hanna Sjöström, CEO Neola Medical